Dr. Frances Shepherd CV - (NCRI) is

100. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl NB.
Derivation of utility values from European Organization for Research and Treatment of Cancer
Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010; 12: 1953-7.
101. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F,
Shepherd FA, Tsao MS. The Ability to Form Primary Tumour Xenografts is Predictive of Increased
Risk of Disease Recurrance in Early Stage Non-small Cell Lung Cancer. Clin Cancer Res. 2011; 17:
134-41.
102. Addison CL, Ding K, Zhao H, Le Maitre A, Goss GD, Seymour L, Tsao MS, Shepherd FA,
Bradbury PA. Plasma Transforming Growth Factor alpha and Amphiregulin Protein Levels in NCIC
Clinical Trials Group BR.21. J Clin Oncol. 2010; 28: 5247-56.
103. Boutros PC, Pintilie M, John T, Starmans MH, Der SD, Shepherd FA, Tsao MS, Jurisica I.
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer
Inst. 2010; 102: 1677-8.
104. Da Cunha Santos G, Shepherd FA. EGFR Mutations and Lung Cancer. Annu Rev Pathol.
2010; 6: 49-69.
105. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K,
Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS. Prognostic
and predictive gene signature for adjuvant chemotherapy in resected non-small cell lung cancer. J
Clin Oncol. 2010; 28: 4417-24.
106. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Goss G, et al, Shepherd FA.
Randomized Phase III trial of vinorelbione and ciaplatin compared with observation in completely
resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR.10. J Clin Oncol
2010; 28: 29-34.
107. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized
double blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in
advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 49-55.
108. Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in
elderly patients. Cancer. 2010; 116: 1192-200.
109. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer. J
Thorac Oncol. 2010; 5: 723-34.
110. Fruh M, Shepherd FA. Adjuvant cisplatin-based chemotherapy for elderly paitents with
completely resected non-small cell lung cancer: Review of current evidence. Eur J Cancer, Med
Oncol 2010; 2: 59-63.
111. Shepherd FA. Surgery for limited stage small cell lung cancer: time to fish or cut bait. J
Thorac Oncol. 2010; 5: 147-9.
112. Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung
cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol. 2010; 28: 903-5.
113. Vansteenkiste JF, Shepherd FA. The seventh tumor, node, metastases staging system and
lung cancer treatment choices: a matter of would, could, and should. J Thoracic Onc. 2010; 11:
1724-5.
114. Shepherd FA, Maintenance therapy comes of age for non-small-cell lung cancer, but at
what cost? J Clin Oncol 2011; 29: 4068-70.
115. Vallieres E. Vanhoutte P, Travis WD, Rami-Porta R, Goldstraw P, Shepherd FA,
International Association for the Study of Lung Cancer (IASLC) International Staging Committee.
Carcinoma in-situ at the bronchial resection margin: a review. J. Thorac Oncol. 2011; 6: 1617-23.
116. Coate LE, Shepherd FA, Maintenance therapy in advanced non-small cell lung
cancer: evolution, tolerability and outcomes. Ther Avd Med Oncol 2011; 3: 139-57.
117. Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for nonsmall
cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol.
2011; 10: 1763-73.
13